Nemoto R, Hattori K, Uchida K, Shimazui T, Nishijima Y, Koiso K, Harada M
Department of Urology, University of Tsukuba, Ibaraki, Japan.
Cancer. 1990 Aug 1;66(3):509-14. doi: 10.1002/1097-0142(19900801)66:3<509::aid-cncr2820660318>3.0.co;2-#.
Forty-six patients with adenocarcinoma of the prostate were given an intravenous infusion of the thymidine analogue, bromodeoxyuridine (BrdU), 200 mg/m2, at the time of needle biopsy or transurethral resection to label tumor cells in the DNA synthesis phase. The tumor specimens were stained by an indirect immunoperoxidase method with anti-BrdU monoclonal antibody. The BrdU labeling index, S-phase fraction, was determined by counting the number of BrdU-labeled cells in the tissue sections. S-phase fraction correlates with the results of histologic tumor grade, Gleason score, and growth patterns. The higher S-phase fraction may indicate biologic malignancy. Moreover, the degree of heterogeneity concerning S-phase fraction distribution within prostate cancer tissue could be evaluated and the findings compared with the morphologic appearance. The authors results suggest that the measurement of BrdU labeling index in prostate cancer may prove to be a new objective and quantitative assay for biologic potential of individual tumors.
46例前列腺腺癌患者在针吸活检或经尿道切除时静脉输注胸苷类似物溴脱氧尿苷（BrdU），剂量为200mg/m²，以标记处于DNA合成期的肿瘤细胞。肿瘤标本用抗BrdU单克隆抗体通过间接免疫过氧化物酶法染色。通过计数组织切片中BrdU标记的细胞数量来确定BrdU标记指数，即S期分数。S期分数与组织学肿瘤分级、Gleason评分及生长模式的结果相关。较高的S期分数可能表明生物学恶性程度较高。此外，可评估前列腺癌组织内S期分数分布的异质性程度，并将结果与形态学表现进行比较。作者的结果表明，测量前列腺癌中的BrdU标记指数可能成为一种用于评估个体肿瘤生物学潜能的新的客观定量检测方法。
